Biogen Inc (BIIB) is showing signs of resilience with a current price of $179.90, reflecting a 2.44% increase from the previous close of $175.61. The company has consistently beaten earnings estimates, with Q4 2025 actual EPS of $1.99 exceeding estimates by 21.47%. With a market cap of $26.40B and a relatively low P/E ratio of 20.35, BIIB appears undervalued compared to peers in the biotechnology sector, which typically trade at higher multiples.